CLINUVEL PHARMACEUTICALS/ AU000000CUV3 /
2024-09-10 8:36:47 AM | Chg. -0.0350 | Volume | Bid11:43:35 AM | Ask11:43:35 AM | High | Low |
---|---|---|---|---|---|---|
8.8150EUR | -0.40% | 1,499 Turnover: 13,213.6850 |
8.8550Bid Size: 240 | 8.9000Ask Size: 1,620 | 8.8150 | 8.8150 |
GlobeNewswire
03-28
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
GlobeNewswire
2018-12-19
Phase II study: SCENESSE® in combination with narrowband ultraviolet B (NB-UVB) achieves repigmentat...
GlobeNewswire
2018-06-25
FDA to Review Australian Drug for Genetic Disorder of Absolute Light Intolerance
GlobeNewswire
2017-04-12
CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board
GlobeNewswire
2016-06-01
Nasdaq Welcomes Additional Companies to the Nasdaq International Designation